JP2010518860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518860A5 JP2010518860A5 JP2009550979A JP2009550979A JP2010518860A5 JP 2010518860 A5 JP2010518860 A5 JP 2010518860A5 JP 2009550979 A JP2009550979 A JP 2009550979A JP 2009550979 A JP2009550979 A JP 2009550979A JP 2010518860 A5 JP2010518860 A5 JP 2010518860A5
- Authority
- JP
- Japan
- Prior art keywords
- minutes
- substrate
- test compound
- lyn kinase
- atp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 239000000758 substrate Substances 0.000 claims 12
- 108091000080 Phosphotransferase Proteins 0.000 claims 7
- 102000020233 phosphotransferase Human genes 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 102000001253 Protein Kinase Human genes 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical group 0.000 claims 4
- 108060006633 protein kinase Proteins 0.000 claims 4
- 230000026731 phosphorylation Effects 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 0 *c1c(*)c(*)c(*C(C(*)=N2)=C(*)N(*)C2=*)c(*)c1* Chemical compound *c1c(*)c(*)c(*C(C(*)=N2)=C(*)N(*)C2=*)c(*)c1* 0.000 description 2
- -1 5,6,7,8-tetrahydronaphthyl Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89063207P | 2007-02-20 | 2007-02-20 | |
| PCT/US2008/054361 WO2008103692A2 (en) | 2007-02-20 | 2008-02-20 | Methods of identifying activators of lyn kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518860A JP2010518860A (ja) | 2010-06-03 |
| JP2010518860A5 true JP2010518860A5 (enExample) | 2011-04-07 |
Family
ID=39710712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550979A Pending JP2010518860A (ja) | 2007-02-20 | 2008-02-20 | Ｌｙｎキナーゼの活性化剤の同定方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100152215A1 (enExample) |
| EP (1) | EP2120581A4 (enExample) |
| JP (1) | JP2010518860A (enExample) |
| KR (1) | KR20100014480A (enExample) |
| CN (1) | CN101686686A (enExample) |
| AU (1) | AU2008218765A1 (enExample) |
| BR (1) | BRPI0807928A2 (enExample) |
| CA (1) | CA2678813A1 (enExample) |
| IL (1) | IL200429A0 (enExample) |
| MX (1) | MX2009008874A (enExample) |
| NZ (1) | NZ579227A (enExample) |
| WO (1) | WO2008103692A2 (enExample) |
| ZA (1) | ZA200905776B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB201010196D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| CN102507707B (zh) * | 2011-10-12 | 2015-10-21 | 山东大学 | 一种检测龈沟液中蛋白裂解酶含量的方法 |
| SG11201403207WA (en) * | 2011-12-12 | 2014-09-26 | Melior Pharmaceuticals I Inc | Treatment of type i and type ii diabetes |
| WO2015002818A1 (en) * | 2013-07-01 | 2015-01-08 | Emory University | Treating or preventing nephrogenic diabetes insipidus |
| JP6584322B2 (ja) | 2013-12-27 | 2019-10-02 | 国立大学法人 東京医科歯科大学 | アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法 |
| US20210106581A1 (en) | 2018-02-21 | 2021-04-15 | Melior Pharmaceuticals I, Inc. | Treatment Of Liver Diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3922345A (en) * | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| US4080454A (en) * | 1976-07-16 | 1978-03-21 | Pfizer Inc. | 5-M-Tolyloxyuracil, anti-ulcer agent |
| US4612376A (en) * | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
| US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| SE9203753D0 (sv) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| US6900304B2 (en) * | 1996-01-31 | 2005-05-31 | The Regents Of The University Of California | Emission ratiometric indicators of phosphorylation |
| US20020019346A1 (en) * | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
| GB0104422D0 (en) * | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| DE602004008762T2 (de) * | 2003-04-30 | 2008-06-12 | The Institutes for Pharmaceutical Discovery, LLC, Branford | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen |
| EP1541694A1 (en) * | 2003-12-12 | 2005-06-15 | Sirenade Pharmaceuticals AG | Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase |
| US20060035302A1 (en) * | 2004-06-21 | 2006-02-16 | Applera Corporation | Kinase substrates with multiple phosphorylation sites |
| US7652009B2 (en) * | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
| ITUD20050112A1 (it) * | 2005-07-01 | 2007-01-02 | Gaetano Azzolina | Dispositivo di assistenza cardiocircolatoria |
| TWI273177B (en) * | 2005-07-08 | 2007-02-11 | Ama Precision Inc | Fan apparatus with adapting device |
| WO2007016975A1 (en) * | 2005-07-29 | 2007-02-15 | F. Hoffmann-La Roche Ag | Kinase and phosphatase assays based on fret |
| EP1924262B1 (en) * | 2005-08-22 | 2011-11-16 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating lyn kinase activity and treating related disorders |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
-
2008
- 2008-02-20 JP JP2009550979A patent/JP2010518860A/ja active Pending
- 2008-02-20 AU AU2008218765A patent/AU2008218765A1/en not_active Abandoned
- 2008-02-20 CA CA002678813A patent/CA2678813A1/en not_active Abandoned
- 2008-02-20 EP EP08730208A patent/EP2120581A4/en not_active Withdrawn
- 2008-02-20 NZ NZ579227A patent/NZ579227A/xx not_active IP Right Cessation
- 2008-02-20 US US12/527,801 patent/US20100152215A1/en not_active Abandoned
- 2008-02-20 CN CN200880012768A patent/CN101686686A/zh active Pending
- 2008-02-20 KR KR1020097019560A patent/KR20100014480A/ko not_active Withdrawn
- 2008-02-20 BR BRPI0807928-5A patent/BRPI0807928A2/pt not_active IP Right Cessation
- 2008-02-20 MX MX2009008874A patent/MX2009008874A/es not_active Application Discontinuation
- 2008-02-20 WO PCT/US2008/054361 patent/WO2008103692A2/en not_active Ceased
-
2009
- 2009-08-17 IL IL200429A patent/IL200429A0/en unknown
- 2009-08-19 ZA ZA200905776A patent/ZA200905776B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109414596B (zh) | Ash1l抑制剂和用其进行治疗的方法 | |
| Mahapatra et al. | New solid state forms of the anti-HIV drug efavirenz. Conformational flexibility and high Z′ issues | |
| KR101762999B1 (ko) | 종양 치료제 | |
| MY150289A (en) | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | |
| RU2008108898A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| JP2007517807A5 (enExample) | ||
| BRPI0615111B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
| CA2616451C (en) | Substituted benzyl derivatives as gsk-3 inhibitors | |
| TR201807023T4 (tr) | Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. | |
| JP2015143283A5 (enExample) | ||
| KR20100101056A (ko) | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 | |
| RS57658B1 (sr) | Novi derivati benzimidazola kao inhibitori kinaza | |
| CA2650326A1 (en) | N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors | |
| RU2014134909A (ru) | Азагетероциклические соединения | |
| JP2010535180A5 (enExample) | ||
| Li et al. | Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group | |
| KR20120044281A (ko) | 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법 | |
| HUP0202399A2 (hu) | Dopamin D3 receptor ligandumok alkalmazása veseelégtelenség kezelésére szolgáló gyógyszerek előállítására | |
| CN101505755B (zh) | 抗癌药耐性克服剂 | |
| JP2005538944A5 (enExample) | ||
| JP2013537240A5 (enExample) | ||
| EP4126815A1 (en) | Stable heavy isotopes in amide functional groups and uses thereof | |
| CA3245082A1 (en) | PCNA INHIBITORS AND RELATED USES | |
| US20120214810A1 (en) | Salts of N-[6-cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide | |
| CN105050602A (zh) | 作为pi3激酶抑制剂的吡啶化合物 |